Preliminary results of a randomized phase II trial of chidamide plus fulvestrant with or without sintilimab in HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (CISFORT).

Epidaza (chidamide) - Chipscreen

fulvestrant - Generic mfg.

Tyvyt (sintilimab) - Innovent Biologics, Eli Lilly

https://www.asco.org/abstracts-presentations/263463/

Haifeng Li; Qixiang Rong; Riqing Huang; Meiting Chen; Qiufan Zheng; Cong Xue; Yanhong Su; Xin An; Yanxia Shi

Apr 21, 2026